Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

GoodRx shares are pulling back Tuesday morning. The stock had jumped over 30% Monday after the company announced a new ...

GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...

GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.

In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...

GoodRx (Nasdaq: GDRX) has teamed up with Novo Nordisk (NOV: N) to make all dose levels of Ozempic (semaglutide) and Wegovy ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...